...Running head: WESTERN PHARMACEUTICALS Case Analysis 6 and 7: Western Pharmaceuticals (A&B) MGT 309 Mirtha Professor 20 th September 20, 2015 WESTERN PHARMACEUTICALS Case Analysis 6 and 7: Western Pharmaceuticals (A&B) Background George's grandfather established Western Pharmaceutical (An) in Los Angeles. George, who is the CEO of the recently framed United Pharmaceuticals, chose to have Western Pharmaceuticals (A) merge with one of the biggest over-the-counter icy core business, Atlantic Medical. This merger was to assist ensure coastal market entrance for both Western's disturbed stomach items and Atlantic's coughing syrups. Western Pharmaceutical (B) is an expansion of Western Pharmaceutical (A). It obliges a stock examination concentrating on deciding inventory prerequisites. In spite of the fact that the firm needed a far-reaching inventory investigation, the data accessible was constrained because of the merger and a concurrent move to an Enterprise Resource Planning System. Issues Addressed The case utilizes an unordinary methodology of duplicating the demanded quantity at the service level to gauge the resultant sales rather than demand. The procedure will focus on a weighted service level. Sections, AN, AO, and AM, shows the weighted sales for each DC item joined. The AQ segment is the aggregate amount of deals in DC and section AR is the total quantity of the interest for DC. The usual service rate is indicated in section AQ and AR. The...
Words: 2520 - Pages: 11
...Case 8 Western Pharmaceuticals (A) Overview Western Pharmaceuticals (A) is a supply chain network design case placed in the setting of a merger of two firms, Western Pharmaceutical and Atlantic Medical. While their product lines don’t overlap, there is definite overlap in their distribution systems. Both the demand and cost data is provided in spreadsheets to facilitate a total cost analysis. This case provides students with a comprehensive and realistic distribution center location problem that can be solved using a spreadsheet analysis. While the analysis can be completed using a supply chain design planning tool such as CAPS, Supply Chain Planner, Supply Chain Navigator, or Logic*Net, it is often useful to have the students completed the analysis using a spreadsheet so they develop some insight regarding the logic and dynamics of such planning tools. This case can also be used to illustrate and apply the Logistics Planning Process discussed in Chapter 16. This case is an effective tool for students understand the process of developing a total cost model and then using it to determine relevant total cost curves includes the major logistics cost components. Solution The first step in solving the case is to define the critical assumptions for completing analysis. Specific assumptions include: 1. All demand is assigned to a single point within each state. A representative point is the capitol or the largest city; 2. All demand is shipped to customers in...
Words: 1893 - Pages: 8
...REGINA E. HERZLINGER NATALIE KINDRED Shanghai Pharmaceuticals With 2011 revenues of $8.67 billion, 1 Shanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, produced active pharmaceutical ingredients (APIs), chemical and biological drugs, and traditional Chinese medicines (TCMs); distributed its own and other drug makers’ products to hospitals and other customers; and operated a chain of retail pharmacies. The company—essentially a collection of subsidiaries operating under a unified management structure— was formed through the 2009 merger of several state-owned enterprises (SOEs), part of a broad policy effort in China to streamline state assets, consolidate the fragmented pharmaceutical sector, and enhance the global competitiveness of domestic firms. Emblematic of China’s hybrid economic policies, SPH had both government and private shareholders and competed in a historically statecontrolled industry that was adapting to the growing influence of market forces. SPH’s initial public offering (IPO) on the Hong Kong Stock Exchange in 2011 marked an important step in its quest to transform from a traditional SOE into a market-oriented company. While working to expand SPH’s domestic footprint, the company’s leadership was also considering a potential acquisition of a U.S. or European drug producer, an unusual move for a Chinese company. SPH could leverage such an acquisition to learn from Western research and development (R&D), manufacturing...
Words: 12061 - Pages: 49
...1990, Ricerca, Inc. was acquired by Ishihara Sangyo Kaisha and shifted its focus to providing pharmaceutical research services. By 2002, the company had changed its name to Ricerca Biosciences, LLC to reflect its growing biology and biotechnology capabilities for the preclinical development of pharmaceutical and biotechnology products. Sustained by successful customer relations and partnering relationships, Ricerca Biosciences has grown to employ approximately 850 employees in the US, France and Taiwan (http://www.medcitynews.com/2010/03/ricerca-biosciences-completes-35m-buy-of-mds-pharma-units/), with 265 employees stationed at the Concord facility and 585 employees in the US and abroad. The current focus of Ricerca Bioscience is to offer a well-balanced integration of biological and medicinal chemistry services for the development of pharmaceutical and biotechnology products through the pre-clinical stage to the IND stage. Ricerca also provides continued support in CMC development, late stage non-clinical toxicology and metabolisms studies, and clinical sample analysis (http://www.ricerca.com/page12919.asp). Leadership Team R. Ian Lennox-Executive Chairman and Chief Executive Officer Mr. Lennox was appointed Chief Executive Officer position at Ricerca in February 2008 and has been a member of Ricerca’s Board since 2006. Mr. Lennox has spent over 30 years in the pharmaceutical and...
Words: 1212 - Pages: 5
...OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARDLOOKING STATEMENTS. IMPORTANT FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE RISKS RELATING TO: TEVA'S ABILITY TO ACCURATELY PREDICT FUTURE MARKET CONDITIONS, TEVA'S ABILITY TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE ADDITIONAL PHARMACEUTICAL PRODUCTS, THE INTRODUCTION OF COMPETING GENERIC EQUIVALENTS, THE EXTENT TO WHICH TEVA MAY OBTAIN U.S. MARKET EXCLUSIVITY FOR CERTAIN OF ITS NEW GENERIC PRODUCTS AND REGULATORY CHANGES THAT MAY PREVENT TEVA FROM UTILIZING EXCLUSIVITY PERIODS, COMPETITION FROM BRAND-NAME COMPANIES THAT ARE UNDER INCREASED PRESSURE TO COUNTER GENERIC PRODUCTS, OR COMPETITORS THAT SEEK TO DELAY THE INTRODUCTION OF GENERIC PRODUCTS, POTENTIAL LIABILITY FOR SALES OF GENERIC PRODUCTS PRIOR TO A FINAL RESOLUTION OF OUTSTANDING PATENT LITIGATION, INCLUDING THAT RELATING TO THE GENERIC VERSIONS OF ALLEGRA , NEURONTIN , LOTREL , FAMVIR , AND PROTONIX , THE IMPACT OF CONSOLIDATION OF OUR DISTRIBUTORS AND CUSTOMERS, THE EFFECTS OF COMPETITION ON OUR INNOVATIVE PRODUCTS, ESPECIALLY COPAXONE SALES, THE IMPACT OF PHARMACEUTICAL INDUSTRY REGULATION AND PENDING LEGISLATION THAT COULD AFFECT THE PHARMACEUTICAL INDUSTRY, THE DIFFICULTY OF PREDICTING U.S. FOOD AND DRUG ADMINISTRATION, EUROPEAN MEDICINES AGENCY AND OTHER REGULATORY AUTHORITY APPROVALS, THE REGULATORY ENVIRONMENT AND CHANGES IN THE HEALTH POLICIES AND STRUCTURES OF VARIOUS COUNTRIES, OUR ABILITY TO ACHIEVE EXPECTED RESULTS THOUGH OUR...
Words: 7679 - Pages: 31
...IMPACT OF TOTAL QUALITY MANAGEMENT IN INDIAN PHARMACEUTICAL COMPANIES’ PERFORMANCE Name: Singh Sudhanshu Bala, Roll no.- ITM/BIT/MUMBAI/09/1- 17 2. INDEX Serial No. Title Page No. 1. Title Page 1 2. Index 2 3. Title of the Thesis 3 4. Background of Research 4 5. Objectives 10 6. Scope 11 7. Methodology 11 8. Review of Literature 12 9. Gaps in Literature 14 10. Summary of the Proposal 14 11. Work Plan 16 12. References 17 3. TITLE OF THE THESIS: IMPACT OF TOTAL QUALITY MANAGEMENT IN INDIAN PHARMACEUTICAL COMPANIES’ PERFORMANCE 4. BACKGROUND OF RESEARCH: Total quality management (TQM) - TQM has been defined as an integrated organizational effort designed to improve quality at every level. TQM is also defined as quest of excellence, fitness for use, value for money, customer satisfaction etc. The International Organisation for Standards (ISO) defines TQM as, "TQM is a management approach for an organisation, centered on quality, based on the participation of all its members and aiming at long-term success through customer satisfaction and benefits to all members of the organisation and to society." ISO 8402:1994 TQM acts as an umbrella under which everyone in the organisation...
Words: 3769 - Pages: 16
...FIN-516 – WEEK 2 – MINI – CASE Merck & Co., Inc. by M. Luisa Ribeiro 1. Merck & Co., Inc. is a company in the Pharmaceutical Sector. The headquarters are in Whitehouse Station, NJ but it has global presence providing prescription pharmaceuticals, animal health, and consumer care, which include animal health, consumer care products and pharmaceutical medicines which include vaccines, biologic therapies. Merck’s products are marketed directly and through joint ventures. 2. Merck’s operating risks: Merck’s operating risks include recently expired and expiring patented medications which are and soon will be facing market competition from generics, and fewer that optimal products in the development stage to be brought to market. Additionally, some European countries, in an effort to reduce and curtail costs as they are coping with the effects of austerity measures, are imposing a mandatory switch to generic drugs. Some disappointing results of new products in the development stage are posing a risk to the company that needs to stay in compliance, particularly in the face of law suits for past and current medications under Merck’s patent. With changing environment in the health care field in the US, Merck’s efforts to expand operations and distribution to developing countries, also posed a challenge to the company, as developing regions, such as Africa and developing countries such as India, China, Russia and Brazil, that may not offer a stable political, regulatory...
Words: 1473 - Pages: 6
...Case Differential pricing of pharmaceuticals: the HIV / AIDS Crisis 1) Is the monopoly on patented pharmaceuticals warranted? What barrier to entry prevents the re-importation into the United States of pharmaceuticals sold at lower prices abroad (say, in Canada)? The monopoly on patented pharmaceuticals is an improper term, and represents only a limited warranty. * First, it is limited in time. The company needs to recover its R&D investment and make a fair profit during the period of exclusivity. * Second, it is limited geographically – as some countries will not respect intellectual property and allow their own pharmaceutical companies to copy innovations, making generic drugs even before the original patent expires. * Third, it lacks the most important element of a monopoly: price control. In most countries, the prices of drugs are set by a governmental agency. The manufacturers are merely consulted; their influence is very limited. In the end, once the price is set, they can only decide if they are willing to sell at that price or not. Take it or leave it. * The combinations of the factors above will put pressure on the pharmaceutical companies to expand geographically as quickly as possible, in order to maximize their chances of recovering their R&D costs and making a fair profit within the time period covered by patent protection. In order to do that, they will accept in some countries prices that are far from ideal – prices they would...
Words: 1295 - Pages: 6
...CASE TEACHING NOTES The Global Pharmaceutical Industry Sarah Holland (Manchester Business School) and Bernardo Bátiz-Lazo (London South Bank University) 1. Introduction The case describes how the prescription pharmaceutical industry has changed since its modern beginnings in the early 1950s. The various forces affecting the competitive environment of the industry are discussed in terms of origins, immediate past and immediate future (2004 onwards). As a result, the note provides insights into the evolution of barriers to enter and exit the industry for prescription pharmaceuticals, while aiming to help students to recognise how to set boundaries for an industry. This is a detailed industry note on the “ethical” pharmaceutical industry which provides an opportunity to analyse key success factors of major players. The note centres on a descriptive overview of the predominant issues in the three major Triad market areas: the US, Europe and Japan (although major issues in emerging markets are also mentioned). The note covers the overall industry environment with in-depth discussion of the driving forces in the industry such as globalisation (in particular global regulatory issues, changing world demographics and worldwide pricing disparities); development of new technology; the importance of time to market; and amalgamations. The case also examines issues around corporate social responsibility. 2. Position of the Case The pharmaceutical industry case study lends itself...
Words: 8602 - Pages: 35
...Statistics, “Traditional Chinese Medicine exports rose in 2011, with exports to the US alone jumping by 66.3% year on year.” The use and practice of TCM has expanded and spread to other countries, and is currently affecting many individuals. From this fact, this paper aims to study Traditional Chinese Medicine (or TCM) because of its current and possible future situation. Its course of development, evolution, impact on society, and acceptance in the medical field will be thoroughly discussed and analyzed in this paper. There are two reasons as to why this study should be taken. The first is to find out if alternative medicine, specifically Traditional Chinese Medicine, can be considered another plausible treatment for diseases apart from pharmaceutical drugs. The second reason is because it is an ongoing practice that involves many people today, which is why its possible future should be predicted and studied. Contributions of the study: Chinese traditional medicine has contributed many things. It mainly helped in discoveries, studies, and developments. Chinese traditional medicine discovered the many medical uses of plants and animals. They discovered that Astragalus roots can be used to strengthen the heart and prevent heart disease. Schisandra, otherwise known as Magnolia vine, is used to treat Tussis (coughs) Rhino sinusitis (colds) and fatigue. Another plant that they discovered was the Chrysanthemum, which helped cure fevers, flus, and headaches. Another discovery...
Words: 2821 - Pages: 12
...maintaining good human relations in the organisation. It is also concerned with development of individuals and achieving integration of goals of the organisation and those of the individuals. Northcott considers human resource management as an extension of general management, that of prompting and stimulating every employee to make his fullest contribution to the purpose of a business. Human resource management is not something that could be separated from the basic managerial function. It is a major component of the broader managerial function. French Wendell, defines ―Human resource management as the recruitment, selection, development, utilisation, compensation and motivation of human resources by the organisation‖. According to Edwin B. Flippo, ―Human resource management is the planning,...
Words: 9061 - Pages: 37
...International Marketing: Entering New Markets By: Div B TURKEY WHY CIPLA IN TURKEY Attractive Emerging Market Alignment with Cipla’s Corporate Vision Government Initiative (Vision 2023) Geo-strategic importance Disease Prevalence • Respiratory diseases- 3rd major cause of death • Cancer- 2nd major cause of death • 60% adult men and 40% adult women smoke in Turkey • HIV- Officially 1/2 in Istanbul Wholesale Retail • More than 500 wholesale companies, but only about 200 of them are active •More than 24,000 pharmacies • Selçuk Ecza and Hedef Alliance>90% of wholesale market share •Istanbulmaximum pharmacies •Mark ups are regulated HOW TO ENTER TURKEY Turkey Government’s Vision 2023 HOW TO ENTER TURKEY Turkey Government’s Vision 2023 In “Vision 2023” scenario for Turkey’s pharmaceutical industry, the ratio of locally manufactured products to market size will increase and reach USD 16 billion by 2023. HOW TO ENTER TURKEY Turkey Government’s Vision 2023 In “Vision 2023” scenario, clinical research investments are expected to reach USD 1.1 billion and total R&D investment by pharmaceutical industry is expected to reach USD 1.7 billion. HOW TO ENTER TURKEY Turkey Government’s Vision 2023 Turkey’s pharma export rate is expected to remain stable under current policies, but it could reach USD 8.1 billion as a result of increased production and clinical trial capacity in the “Vision...
Words: 547 - Pages: 3
...China’s socialist ideology was accompanied by an erosion of the government’s subsidy of health services, placing the major responsibilities of providing health care services on regional governments. Unfortunately, the impact of these policies on China’s health care system is not commonly understood, resulting in confusion and propagation of myths. For example, many believe that the Chinese government provides free health care for all citizens, and the population has not accepted Western medicine and relies primarily on traditional Chinese medicine. In addition, it is believed that there is no shortage of nurses, as the majority of care is provided at home. Finally, it is commonly believed that China’s health care issues are different from those of the United States. Exploration of these myths provides us with a better understanding and an improved ability to engage with this emerging economic global leader. Key words: China, Complimentary Therapies, Nursing, Traditional Chinese medicine, Western Medicine HINA’S EMERGING PRESENCE in the global economy has been accompanied by significant shifts in the country’s domestic policy, especially in the area of health care. Erosion of the socialist ideology that shaped China’s political landscape after the World War II is clearly apparent in the country’s market reform...
Words: 8043 - Pages: 33
...PHRMA Table of Contents 1) Introduction page 3 2) History/Overview of the Industry page 3 3) Economic Characteristics page 4 a) Structure b) Costs c) Demand d) Competition- The Rise of the Generics e) Market Failure, Government Intervention and Price 4) Performance page 7 5) Impact of the Global Economic Downturn page 9 6) Summary page 10 7) Conclusion page 11 Bibliography page 12 8) 1. Introduction This paper briefly examines the current state of the pharmaceutical industry, as well as the economic characteristics, performance, and the impact of the global recession. The industry is made up of several enterprises engaging in the research, development, manufacture and marketing of medicines, vaccines, medical devices, and nutritional products for humans and animals. Though, this multi-billion dollar industry includes large ethical drug multi-nationals (often referred to as Big Pharma), mid-sized specialty pharmaceutical companies, manufacturers of generics, small biotechnology and biopharmaceutical firms, and service companies, 1 for the purpose of this paper, the emphasis will be mainly on drug makers. 2. History/Overview of the Industry The pharmaceutical industry of today is a far cry from its humble beginnings in the nineteenth century of physicians mainly prescribing plant extracts to being technology intensive, dominated by a few large...
Words: 2796 - Pages: 12
...Dr. Reddy’s Laboratories Ltd At Dr. Reddy’s strives every day to do what matters most to patients: accelerating access to affordable medicines and finding solutions for unmet needs. Company’s Generics products bring expensive medicines within reach of patients by helping reduce the cost of therapy. Company’s portfolio consists of all dose forms in multiple therapeutic areas as well as biologic drugs. Company also serves patients through it’s partners. For one, company supply other generics companies with active pharmaceutical ingredients, which helps them quickly bring medicines to market and create affordable options to high cost medicines. Company also helps innovator companies get their proprietary medicines to patients faster by providing a range of products and services. To address unmet patient needs, company develops innovative products that increase patient convenience and/or enhance a drug’s safety or efficacy. These include novel formulations of currently marketed drugs or combinations of complementary drugs that address significant unmet needs. Company also have an active drug discovery program to discover and develop new chemical entities in key therapeutic areas. To help manage disease better company go beyond providing medicines. In ailments such as cancer, hypertension, diabetes and kidney disease, company provide services that help stay on course with prescribed treatments through daily reminders about medication and follow-up as needed, facilitate counselling...
Words: 1937 - Pages: 8
